Darapladib 160 mg

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Acute Coronary SyndromeAtherosclerosis

Phase 1

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

CompletedNCT01711723

GlaxoSmithKlineAtherosclerosis

Start: 2012-10-29End: 2013-03-25Updated: 2017-07-26

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

CompletedNCT01751074

GlaxoSmithKlineAtherosclerosis

Start: 2012-12-17End: 2013-03-14Updated: 2017-07-26

Phase 3

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

CompletedNCT01000727

GlaxoSmithKlineAcute Coronary Syndrome

Start: 2009-12-01End: 2014-04-24Updated: 2017-08-10

Related Papers

Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease

European Journal of Preventive Cardiology2025-10-27

Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trials

American Journal of Epidemiology2025-10-08

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome

Journal of the American Heart Association2018-10-1252 citations

Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome

Journal of the American Heart Association2017-10-1174 citations

Predictors of Nonuse of a High‐Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib‐Thrombolysis in Myocardial Infarction 52 (SOLID‐TIMI 52) Trial

Journal of the American Heart Association2017-01-1112 citations

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome

JAMA2014-08-31447 citations

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

PLoS ONE2014-01-2722 citations